Earlier, we demonstrated the feasibility of designing third-generation CARs and generating CAR-NK-92 cells targeting CD19, CD138, or other tumor antigens, which support the idea of generating a library of CAR-NK cells targeting different antigens for the personalized proof of concept [15]. This evidence concerns the gene CD19 and neoplasm.